Kronik Myeloid Lösemide Tanı Anında İlave Kromozomal Abnormaliteler ve Varyant Philadephia Translokasyonları; Tek Merkez Deneyimi

Çiğdem Aydın Acar; Zafer Çetin; Orhan Kemal Yücel; Utku Iltar; Ozan Salim; Sibel Berker Karaüzüm

doi:10.17343/sdutfd.535002

Kronik Myeloid Lösemide Tanı Anında İlave Kromozomal Abnormaliteler ve Varyant Philadephia Translokasyonları; Tek Merkez Deneyimi

Abstract

Amaç: Kronik miyeloid lösemi (KML) hastalarında Philadelphia (Ph) kromozomunun yanında, ilave kromozom anomalilerin varlığı hastalık progresyonu ile ilişkili klonal evrimi göstermektedir. Bu nedenle, geniş hasta serilerinde sitogenetik analiz sonuçlarının değerlendirilmesi, KML hastalarında tanı kadar, hastalığın prognozu açısından da büyük öneme sahiptir.

Gereç ve Yöntem: Bu çalışmada, KML tanılı 225 hastanın kemik iliği örneklerinden elde edilmiş sitogenetik ve FISH analiz sonuçları retrospektif olarak incelenmiştir.

Bulgular: 225 hastanın 15’inde (%6,7) klasik Ph kromozomuna ilave kromozomal abnormalite belirlenmiştir. Bu hastalardan 2’sinde minör rota (%0,9), 10’unda majör rota (%4,4) kromozom anomalileri, ayrıca 3 hastada sırasıyla ilave kromozom anomalisi olarak t(8;19), t(5;7) ve 16 numaralı kromozomun kaybı gözlenmiştir. İlave kromozomal abnormaliteler içerisinde en yaygın olarak ikinci bir Ph kromozomunun varlığı ve bunu takiben 8 ve 19 numaralı kromozomların trizomisi belirlenmiştir. 225 hastanın 7’sinde (%3,1) ise varyant philadelphia kromozom translokasyonu gösterilmiştir ve bu varyant translokasyonlardan t(X;9;22)( p11.4;q34;q11) ve t(20;9;22)(p13;q34;q11) ise bizim çalışmamızda ilk kez rapor edilmiştir.

Sonuç: Çalışmamızda sonuç olarak, t(9;22) translokasyonuna ilave kromozom abnormalitelerinin ve varyant Ph translokasyonlarının KML kliniği ile ilişkisi ve literatüre göre değerlendirilmesi yapılmıştır.

Keywords

Kronik miyeloid lösemi,İlave kromozom anomalileri,KML

References

1. Hehlmann R, Hochhaus A, Baccarani M; European LeukemiaNet. Chronic myeloid leukaemia. Lancet 2007;370:342-50.
2. Crisan AM, Coriu D, Arion C, Colita A, Jardan C. The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia. J Med Life. 2015 Oct-Dec;8(4):502-8.
3. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101(10): 3794-3800.
4. O’Dwyer ME, Mauro MJ, Blasdel C, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood. 2004;103(2):451-455.
5. Skorski T. BCR/ABL, DNA damage and DNA repair: Implications for new treatment concepts. Leuk Lymphoma. 2008;49(4):610-614.
6. Safaei A, Monabati A, Safavi M, Atashabparvar A, Hosseini M. Additional cytogenetic aberrations in chronic myeloid leukemia: a single-center experience in the Middle East. Blood Res. 2018 Mar;53(1):49-52. doi: 10.5045/br.2018.53.1.49.
7. Syed NN, Usman M, Adil S, Khurshid M. Additional chromosomal abnormalities in Philadelphia-positive chronic myeloid leukemia. Hematol Oncol Stem Cell Ther. 2008 Jul-Sep;1(3):166-70.
8. Mitelman F, Levan G, Nilsson PG, Brandt L. Nonrandom karyotypic evolution in chronic myeloid leukemia. Int J Cancer. 1976;18(1):24-30.

9. Mitelman F. The Cytogenetic Scenario of Chronic Myeloid Leukemia. Leuk Lymphoma. 1993; 11(s1):11-15.
10. Millot F, Dupraz C, Guilhot J, Suttorp M, Brizard F, Leblanc T, Güneş AM, Sedlacek P, De Bont E, Li CK, Kalwak K, Lausen B, Culic S, Dworzak M, Kaiserova E, De Moerloose B, Roula F, Biondi A, Baruchel A, Guilhot F. Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents. Cancer. 2017 Sep 15;123(18):3609-3616. doi: 10.1002/cncr.30767.
11. Bacher U, Haferlach T, Hiddemann W, Schnittger S, Kern W, Schoch C. Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genet Cytogenet. 2005 Feb;157(1):53-61.
12. McGowan-Jordan J,‎ Simons A,‎ Schmid M. ISCN 2016: An International System for Human Cytogenomic Nomenclature (2016) Cytogenetic and Genome Research 2016, Vol. 149, No. 1-2 1st Edition
13. Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011 Dec 22;118(26):6760-8. doi: 10.1182/blood-2011-08-373902
14. Luatti S, Castagnetti F, Marzocchi G, et al; Gruppo Italiano Malat-tie Ematologiche dell’Adulto (GIMEMA) Working Party on CML. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood. 2012;120: 761-767.
15. O'Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003;17: 481-7.
16. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer. 2007 Jun;7(6):441–453. doi: 10.1038/nrc2147.
17. Anastasi J, Feng J, Le Beau M, et al. The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. Leukemia. 1995 Apr;9(4):628–633.
18. Sessarego M, Panarello C, Coviello DA, et al. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Cancer Genet. Cytogenet. 1987;25:73–80.
19. Cortes J, Talpaz M, O’Brien S, et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006;106:1306-1315.
20. Baccarani M, Deininger MW, Rosti G, et al. European Leukemia-Net recommendations for the management of chronic myeloid leu-kemia. Blood. 2013;122:872-884.
21. Albano F, Specchia G, Anelli L, et al. Genomic deletions on other chromosomes involved in variant t(9;22) chronic myeloid leukemia cases. Genes Chromosomes Cancer 2003;36:353-60. 12.
22. El-Zimaity MM, Kantarjian H, Talpaz M, et al. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 2004;125:187-95.
23. Marzocchi G, Castagnetti F, Luatti S, et al. Variant Philadelphia translocations: molecular‐cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood. 2011;117:6793-6800.
24. Gorusu M, Benn P, Li Z, Fang M. On the genesis and prognosis of variant translocations in chronic myeloid leukemia. Cancer Genet Cytogenet. 2007;173:97-106.
25. Eyüpoğlu D, Bozkurt S, Haznedaroğlu İ, Büyükaşık Y, Güven D. The impact of variant Philadelphia chromosome translocations on the clinical course of chronic myeloid leukemia. Turk J Haematol 2016;33:60-5.
26. Legues ME, Encina A, Valenzuela M, Palma T, Undurraga MS. Cytogenetic and molecular characteristics of 25 Chilean patients with a variant Ph translocation. Cancer Genet. 2011 Jul;204(7):410-2. doi: 10.1016/j.cancergen.2011.06.004.
27. Turchini MF, Geneix A, Delarocque A, Mathe O, Carsuza D, Malet P. Translocation (2;9;22) in chronic myelogenous leukemia (CML). Cancer Genet Cytogenet. 1984 Feb;11(2):221-2.
28. Guillaume B, Ameye G, Libouton JM, Dierlamm J, Vaerman JL, Straetmans N, Ferrant A, Verellen-Dumoulin C, Michaux L. Chronic myeloid leukemia with a rare variant Philadelphia translocation; t(9;22;21)(q34;q11;q22). Cancer Genet Cytogenet. 2000 Jan 15;116(2):166-9.
29. Jeandidier E, Dastugue N, Mugneret F, Lafage-Pochitaloff M, Mozziconacci MJ, Herens C, Michaux L, Verellen-Dumoulin C, Talmant P, Cornillet-Lefebvre P, Luquet I, Charrin C, Barin C, Collonge-Rame MA, Pérot C, Van den Akker J, Grégoire MJ, Jonveaux P, Baranger L, Eclache-Saudreau V, Pagès MP, Cabrol C, Terré C, Berger R; Groupe Français de Cytogénétique Hématologique (GFCH). Abnormalities of the long arm of chromosome 21 in 107 patients with hematopoieticdisorders:a collaborative retrospective study of the Groupe Français de Cytogénétique Hématologique. Cancer Genet Cytogenet. 2006 Apr 1;166(1):1-11.
30. Dube I, Dixon J, Beckett T, Grossman A, Weinstein M, Benn P, McKeithan T, Norman C, Pinkerton P. Location of breakpoints within the major breakpoint cluster region (bcr) in 33 patients with bcr rearrangement-positive chronic myeloid leukemia (CML) with complex or absent Philadelphia chromosomes. Genes Chromosomes Cancer. 1989 Vol 1:106-111
31. Naumann S, Decker HJ. Genesis of variant Philadelphia chromosome translocations in chronic myelocytic leukemia. Cancer Genet Cytogenet. 2003 Nov;147(1):18-22.
32. Richebourg S, Eclache V, Perot C, Portnoi MF, Van den Akker J, Terré C, Maareck O, Soenen V, Viguié F, Laï JL, Andrieux J, Corm S, Roche-Lestienne C; Fi-LMC Group. Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy. Cancer Genet Cytogenet. 2008 Apr 15;182(2):95-102. doi: 10.1016/j.cancergencyto.2008.01.005.
33. Costa D, Carrió A, Madrigal I, Arias A, Valera A, Colomer D, Aguilar JL, Teixido M, Camós M, Cervantes F, Campo E. Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2006 Apr 1;166(1):89-93.
34. Hsiao HH, Liu YC, Tsai HJ, Hsu JF, Yang WC, Chang CS, Lin SF. Additional chromosome abnormalities in chronic myeloid leukemia. Kaohsiung J Med Sci. 2011 Feb;27(2):49-54. doi: 10.1016/j.kjms.2010.09.001.
35. Reid AG, Huntly BJ, Grace C, Green AR, Nacheva EP. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol. 2003 May;121(3):419-27.
36. Bennour A, Sennana H, Laatiri MA, Elloumi M, Khelif A, Saad A.Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9.Cancer Genet Cytogenet. 2009 Oct;194(1):30-7. doi: 10.1016/j.cancergencyto.2009.05.010.
37. Costa D, Carrió A, Madrigal I, Arias A, Valera A, Colomer D, Aguilar JL, Teixido M, Camós M, Cervantes F, Campo E. Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2006 Apr 1;166(1):89-93.
38. Dubé I, Dixon J, Beckett T, Grossman A, Weinstein M, Benn P, McKeithan T, Norman C, Pinkerton P. Location of breakpoints within the major breakpoint cluster region (bcr) in 33 patients with bcr rearrangement-positive chronic myeloid leukemia (CML) with complex or absent Philadelphia chromosomes. Genes Chromosomes Cancer. 1989 Sep;1(1):106-11.
39. Duhoux FP, Ameye G, Lambot V, Herens C, Lambert F, Raynaud S et al. Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies. PLoS One. 2011;6(10):e26311. doi: 10.1371/journal.pone.0026311.
40. Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C et al. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol. 2015 Dec;94(12):2015-24. doi: 10.1007/s00277-015-2494-9.
41. Lee SE, Choi SY, Bang JH, Kim SH, Jang EJ, Byeun JY, Park JE, Jeon HR, Oh YJ, Kim M, Kim DW. The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate. Cancer Genet. 2012 Nov;205(11):563-71. doi: 10.1016/j.cancergen.2012.09.003.
42. Markovic VD, Bouman D, Bayani J, Al-Maghrabi J, Kamel-Reid S, Squire JA. Lack of BCR/ABL reciprocal fusion in variant Philadelphia chromosome translocations: a use of double fusion signal FISH and spectral karyotyping. Leukemia. 2000 Jun;14(6):1157-60.
43. Meza Espinoza JP, Judith Picos Cárdenas V, Gutiérrez-Angulo M, González García JR. Secondary chromosomal changes in 34 Philadelphia-chromosome-positive chronic myelocytic leukemia patients from the Mexican West. Cancer Genet Cytogenet. 2004 Jan 15;148(2):166-9.
44. Yehuda O, Abeliovich D, Ben-Neriah S, Sverdlin I, Cohen R, Varadi G, Orr R, Ashkenazi YJ, Heyd J, Lugassy G, Ben Yehuda D. Clinical implications of fluorescence in situ hybridization analysis in 13 chronic myeloid leukemia cases: Ph-negative and variant Ph-positive. Cancer Genet Cytogenet. 1999 Oct 15;114(2):100-7.
45. van der Plas DC, Hermans AB, Soekarman D, Smit EM, de Klein A, Smadja N, Alimena G, Goudsmit R, Grosveld G, Hagemeijer A. Cytogenetic and molecular analysis in Philadelphia negative CML. Blood. 1989 Mar;73(4):1038-44.

Details

Primary Language

Turkish

Subjects

Clinical Sciences

Journal Section

Research Article

Authors

Çiğdem Aydın Acar
0000-0002-1311-2314
Türkiye

Zafer Çetin This is me
Türkiye

Orhan Kemal Yücel This is me
Türkiye

Utku Iltar This is me
Türkiye

Ozan Salim
Türkiye

Sibel Berker Karaüzüm ^* This is me
Türkiye

Publication Date

September 1, 2019

Submission Date

March 3, 2019

Acceptance Date

May 3, 2019

Published in Issue

Year 2019 Volume: 26 Number: 3

DOI

https://doi.org/10.17343/sdutfd.535002

IZ

https://izlik.org/JA43ET35NK

Cite

RIS / Bibtex

APA

Aydın Acar, Ç., Çetin, Z., Yücel, O. K., Iltar, U., Salim, O., & Berker Karaüzüm, S. (2019). Kronik Myeloid Lösemide Tanı Anında İlave Kromozomal Abnormaliteler ve Varyant Philadephia Translokasyonları; Tek Merkez Deneyimi. Medical Journal of Süleyman Demirel University, 26(3), 320-327. https://doi.org/10.17343/sdutfd.535002

AMA

1.Aydın Acar Ç, Çetin Z, Yücel OK, Iltar U, Salim O, Berker Karaüzüm S. Kronik Myeloid Lösemide Tanı Anında İlave Kromozomal Abnormaliteler ve Varyant Philadephia Translokasyonları; Tek Merkez Deneyimi. Med J SDU. 2019;26(3):320-327. doi:10.17343/sdutfd.535002

Chicago

Aydın Acar, Çiğdem, Zafer Çetin, Orhan Kemal Yücel, Utku Iltar, Ozan Salim, and Sibel Berker Karaüzüm. 2019. “Kronik Myeloid Lösemide Tanı Anında İlave Kromozomal Abnormaliteler Ve Varyant Philadephia Translokasyonları; Tek Merkez Deneyimi”. Medical Journal of Süleyman Demirel University 26 (3): 320-27. https://doi.org/10.17343/sdutfd.535002.

EndNote

Aydın Acar Ç, Çetin Z, Yücel OK, Iltar U, Salim O, Berker Karaüzüm S (September 1, 2019) Kronik Myeloid Lösemide Tanı Anında İlave Kromozomal Abnormaliteler ve Varyant Philadephia Translokasyonları; Tek Merkez Deneyimi. Medical Journal of Süleyman Demirel University 26 3 320–327.

IEEE

[1]Ç. Aydın Acar, Z. Çetin, O. K. Yücel, U. Iltar, O. Salim, and S. Berker Karaüzüm, “Kronik Myeloid Lösemide Tanı Anında İlave Kromozomal Abnormaliteler ve Varyant Philadephia Translokasyonları; Tek Merkez Deneyimi”, Med J SDU, vol. 26, no. 3, pp. 320–327, Sept. 2019, doi: 10.17343/sdutfd.535002.

ISNAD

Aydın Acar, Çiğdem - Çetin, Zafer - Yücel, Orhan Kemal - Iltar, Utku - Salim, Ozan - Berker Karaüzüm, Sibel. “Kronik Myeloid Lösemide Tanı Anında İlave Kromozomal Abnormaliteler Ve Varyant Philadephia Translokasyonları; Tek Merkez Deneyimi”. Medical Journal of Süleyman Demirel University 26/3 (September 1, 2019): 320-327. https://doi.org/10.17343/sdutfd.535002.

JAMA

1.Aydın Acar Ç, Çetin Z, Yücel OK, Iltar U, Salim O, Berker Karaüzüm S. Kronik Myeloid Lösemide Tanı Anında İlave Kromozomal Abnormaliteler ve Varyant Philadephia Translokasyonları; Tek Merkez Deneyimi. Med J SDU. 2019;26:320–327.

MLA

Aydın Acar, Çiğdem, et al. “Kronik Myeloid Lösemide Tanı Anında İlave Kromozomal Abnormaliteler Ve Varyant Philadephia Translokasyonları; Tek Merkez Deneyimi”. Medical Journal of Süleyman Demirel University, vol. 26, no. 3, Sept. 2019, pp. 320-7, doi:10.17343/sdutfd.535002.

Vancouver

1.Çiğdem Aydın Acar, Zafer Çetin, Orhan Kemal Yücel, Utku Iltar, Ozan Salim, Sibel Berker Karaüzüm. Kronik Myeloid Lösemide Tanı Anında İlave Kromozomal Abnormaliteler ve Varyant Philadephia Translokasyonları; Tek Merkez Deneyimi. Med J SDU. 2019 Sep. 1;26(3):320-7. doi:10.17343/sdutfd.535002